title: FDA pulls approval for avastin in breast cancer.
abstract: The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Rose
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D017277:Drug Approval / Q000379:methods; D005260:Female; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab